Immune Response of Elderly Individuals to a Live Attenuated Varicella Vaccine
The Oka strain live attenuated varicella-zoster virus (VZV) vaccine was administered subcutaneously to 202 VZV-immune individuals who were 55 to >87 years old. The dose administered varied from 1100 to 12,000 pfu. One cohort received 3000 pfu with a 3000 pfu booster 3 months later. The vaccine wa...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1992-08, Vol.166 (2), p.253-259 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 259 |
|---|---|
| container_issue | 2 |
| container_start_page | 253 |
| container_title | The Journal of infectious diseases |
| container_volume | 166 |
| creator | Levin, Myron J. Murray, Martha Rotbart, Harley A. Zerbe, Gary O. White, C. Jo Hayward, Anthony R. |
| description | The Oka strain live attenuated varicella-zoster virus (VZV) vaccine was administered subcutaneously to 202 VZV-immune individuals who were 55 to >87 years old. The dose administered varied from 1100 to 12,000 pfu. One cohort received 3000 pfu with a 3000 pfu booster 3 months later. The vaccine was well tolerated. VZV-specific immunologic responses were evaluated over a 24-month period. The mean anti-VZV antibody level was significantly increased for 12 months after vaccination. Interferon-γ production in vitro by peripheral blood mononuclear cells (PBMC) of vaccinees was also increased for 6 months after vaccination. Most significantly, VZV-specific proliferating T cells in PBMC of vaccinees were increased in frequency from 1 in 68,000 to 1 in 40,000. This vaccine-enhanced frequency ofVZV-responding T cells is similar to the frequency observed in 35- to 40-year-old adults. Dose and age of the vaccinees did not significantly influence the magnitude of the mean cell-mediated immune response. The data indicate that VZV immunity in the elderly can be boosted by active immunization. If the increased incidence of herpes zoster that accompanies aging results from the natural waning of immunity, active immunization may prevent or attenuate zoster in the elderly. |
| doi_str_mv | 10.1093/infdis/166.2.253 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_73085555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30112921</jstor_id><sourcerecordid>30112921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-ec594a9ff1ac1ad8bfad01b23aeaaca0b8faaf85cc5dc3e91f93d56d7c3ab1a93</originalsourceid><addsrcrecordid>eNpFkE1r3DAQhkVpSbdp770UdCi9eaMPy7aOISTNwobQJF1KLmIsjUCpP7aSHZp_X7XeJnPRwPPOi3gI-cjZmjMtT8LgXUgnvKrWYi2UfEVWXMm6qCouX5MVY0IUvNH6LXmX0gNjrJRVfUSOuBS8UXpFrjZ9Pw9IbzDtxyEhHT097xzG7oluBhceg5uhS3QaKdBteER6Ok04zDChozuIwWLXQd6sDQO-J298TuOHw3tMvl-c351dFtvrr5uz021hZSOnAq3SJWjvOVgOrmk9OMZbIQEBLLC28QC-UdYqZyVq7rV0qnK1ldBy0PKYfFl693H8NWOaTB_Sv58MOM7J1JI1Kk8OsiVo45hSRG_2MfQQnwxn5q9Bsxg02aARJhvMJ58O3XPbo3s5WJRl_vnAIVnofITB5oL_sbJkWlXlS81Dmsb4jCXjXGjBMy8WHtKEv585xJ-mqmWtzOWPe_NNcXV3f7szO_kHvDiVCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73085555</pqid></control><display><type>article</type><title>Immune Response of Elderly Individuals to a Live Attenuated Varicella Vaccine</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><creator>Levin, Myron J. ; Murray, Martha ; Rotbart, Harley A. ; Zerbe, Gary O. ; White, C. Jo ; Hayward, Anthony R.</creator><creatorcontrib>Levin, Myron J. ; Murray, Martha ; Rotbart, Harley A. ; Zerbe, Gary O. ; White, C. Jo ; Hayward, Anthony R.</creatorcontrib><description>The Oka strain live attenuated varicella-zoster virus (VZV) vaccine was administered subcutaneously to 202 VZV-immune individuals who were 55 to >87 years old. The dose administered varied from 1100 to 12,000 pfu. One cohort received 3000 pfu with a 3000 pfu booster 3 months later. The vaccine was well tolerated. VZV-specific immunologic responses were evaluated over a 24-month period. The mean anti-VZV antibody level was significantly increased for 12 months after vaccination. Interferon-γ production in vitro by peripheral blood mononuclear cells (PBMC) of vaccinees was also increased for 6 months after vaccination. Most significantly, VZV-specific proliferating T cells in PBMC of vaccinees were increased in frequency from 1 in 68,000 to 1 in 40,000. This vaccine-enhanced frequency ofVZV-responding T cells is similar to the frequency observed in 35- to 40-year-old adults. Dose and age of the vaccinees did not significantly influence the magnitude of the mean cell-mediated immune response. The data indicate that VZV immunity in the elderly can be boosted by active immunization. If the increased incidence of herpes zoster that accompanies aging results from the natural waning of immunity, active immunization may prevent or attenuate zoster in the elderly.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/166.2.253</identifier><identifier>PMID: 1321859</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Aged ; Aged, 80 and over ; Antibodies ; Antibodies, Viral - blood ; Antigens ; Biological and medical sciences ; Chickenpox Vaccine ; Cohort Studies ; Dose-Response Relationship, Immunologic ; Drug Tolerance ; Female ; Herpes zoster ; Herpes Zoster - immunology ; Herpesvirus 3, Human - immunology ; Human viral diseases ; Humans ; Immunity ; Immunity, Cellular ; Immunization ; Immunization, Secondary ; Infectious diseases ; Interferon-gamma - biosynthesis ; Major Articles ; Male ; Medical sciences ; Middle Aged ; Older adults ; Random Allocation ; T lymphocytes ; T-Lymphocytes - immunology ; Vaccination ; Vaccines, Attenuated - adverse effects ; Vaccines, Attenuated - immunology ; Varicella zoster encephalitis ; Viral diseases ; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology</subject><ispartof>The Journal of infectious diseases, 1992-08, Vol.166 (2), p.253-259</ispartof><rights>Copyright 1992 The University of Chicago</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-ec594a9ff1ac1ad8bfad01b23aeaaca0b8faaf85cc5dc3e91f93d56d7c3ab1a93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30112921$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30112921$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4409564$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1321859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Murray, Martha</creatorcontrib><creatorcontrib>Rotbart, Harley A.</creatorcontrib><creatorcontrib>Zerbe, Gary O.</creatorcontrib><creatorcontrib>White, C. Jo</creatorcontrib><creatorcontrib>Hayward, Anthony R.</creatorcontrib><title>Immune Response of Elderly Individuals to a Live Attenuated Varicella Vaccine</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>The Oka strain live attenuated varicella-zoster virus (VZV) vaccine was administered subcutaneously to 202 VZV-immune individuals who were 55 to >87 years old. The dose administered varied from 1100 to 12,000 pfu. One cohort received 3000 pfu with a 3000 pfu booster 3 months later. The vaccine was well tolerated. VZV-specific immunologic responses were evaluated over a 24-month period. The mean anti-VZV antibody level was significantly increased for 12 months after vaccination. Interferon-γ production in vitro by peripheral blood mononuclear cells (PBMC) of vaccinees was also increased for 6 months after vaccination. Most significantly, VZV-specific proliferating T cells in PBMC of vaccinees were increased in frequency from 1 in 68,000 to 1 in 40,000. This vaccine-enhanced frequency ofVZV-responding T cells is similar to the frequency observed in 35- to 40-year-old adults. Dose and age of the vaccinees did not significantly influence the magnitude of the mean cell-mediated immune response. The data indicate that VZV immunity in the elderly can be boosted by active immunization. If the increased incidence of herpes zoster that accompanies aging results from the natural waning of immunity, active immunization may prevent or attenuate zoster in the elderly.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens</subject><subject>Biological and medical sciences</subject><subject>Chickenpox Vaccine</subject><subject>Cohort Studies</subject><subject>Dose-Response Relationship, Immunologic</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>Herpes zoster</subject><subject>Herpes Zoster - immunology</subject><subject>Herpesvirus 3, Human - immunology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunity, Cellular</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Infectious diseases</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Major Articles</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Older adults</subject><subject>Random Allocation</subject><subject>T lymphocytes</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccination</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Varicella zoster encephalitis</subject><subject>Viral diseases</subject><subject>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1r3DAQhkVpSbdp770UdCi9eaMPy7aOISTNwobQJF1KLmIsjUCpP7aSHZp_X7XeJnPRwPPOi3gI-cjZmjMtT8LgXUgnvKrWYi2UfEVWXMm6qCouX5MVY0IUvNH6LXmX0gNjrJRVfUSOuBS8UXpFrjZ9Pw9IbzDtxyEhHT097xzG7oluBhceg5uhS3QaKdBteER6Ok04zDChozuIwWLXQd6sDQO-J298TuOHw3tMvl-c351dFtvrr5uz021hZSOnAq3SJWjvOVgOrmk9OMZbIQEBLLC28QC-UdYqZyVq7rV0qnK1ldBy0PKYfFl693H8NWOaTB_Sv58MOM7J1JI1Kk8OsiVo45hSRG_2MfQQnwxn5q9Bsxg02aARJhvMJ58O3XPbo3s5WJRl_vnAIVnofITB5oL_sbJkWlXlS81Dmsb4jCXjXGjBMy8WHtKEv585xJ-mqmWtzOWPe_NNcXV3f7szO_kHvDiVCw</recordid><startdate>19920801</startdate><enddate>19920801</enddate><creator>Levin, Myron J.</creator><creator>Murray, Martha</creator><creator>Rotbart, Harley A.</creator><creator>Zerbe, Gary O.</creator><creator>White, C. Jo</creator><creator>Hayward, Anthony R.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920801</creationdate><title>Immune Response of Elderly Individuals to a Live Attenuated Varicella Vaccine</title><author>Levin, Myron J. ; Murray, Martha ; Rotbart, Harley A. ; Zerbe, Gary O. ; White, C. Jo ; Hayward, Anthony R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-ec594a9ff1ac1ad8bfad01b23aeaaca0b8faaf85cc5dc3e91f93d56d7c3ab1a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens</topic><topic>Biological and medical sciences</topic><topic>Chickenpox Vaccine</topic><topic>Cohort Studies</topic><topic>Dose-Response Relationship, Immunologic</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>Herpes zoster</topic><topic>Herpes Zoster - immunology</topic><topic>Herpesvirus 3, Human - immunology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunity, Cellular</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Infectious diseases</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Major Articles</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Older adults</topic><topic>Random Allocation</topic><topic>T lymphocytes</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccination</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Varicella zoster encephalitis</topic><topic>Viral diseases</topic><topic>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Murray, Martha</creatorcontrib><creatorcontrib>Rotbart, Harley A.</creatorcontrib><creatorcontrib>Zerbe, Gary O.</creatorcontrib><creatorcontrib>White, C. Jo</creatorcontrib><creatorcontrib>Hayward, Anthony R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levin, Myron J.</au><au>Murray, Martha</au><au>Rotbart, Harley A.</au><au>Zerbe, Gary O.</au><au>White, C. Jo</au><au>Hayward, Anthony R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune Response of Elderly Individuals to a Live Attenuated Varicella Vaccine</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1992-08-01</date><risdate>1992</risdate><volume>166</volume><issue>2</issue><spage>253</spage><epage>259</epage><pages>253-259</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>The Oka strain live attenuated varicella-zoster virus (VZV) vaccine was administered subcutaneously to 202 VZV-immune individuals who were 55 to >87 years old. The dose administered varied from 1100 to 12,000 pfu. One cohort received 3000 pfu with a 3000 pfu booster 3 months later. The vaccine was well tolerated. VZV-specific immunologic responses were evaluated over a 24-month period. The mean anti-VZV antibody level was significantly increased for 12 months after vaccination. Interferon-γ production in vitro by peripheral blood mononuclear cells (PBMC) of vaccinees was also increased for 6 months after vaccination. Most significantly, VZV-specific proliferating T cells in PBMC of vaccinees were increased in frequency from 1 in 68,000 to 1 in 40,000. This vaccine-enhanced frequency ofVZV-responding T cells is similar to the frequency observed in 35- to 40-year-old adults. Dose and age of the vaccinees did not significantly influence the magnitude of the mean cell-mediated immune response. The data indicate that VZV immunity in the elderly can be boosted by active immunization. If the increased incidence of herpes zoster that accompanies aging results from the natural waning of immunity, active immunization may prevent or attenuate zoster in the elderly.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>1321859</pmid><doi>10.1093/infdis/166.2.253</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1992-08, Vol.166 (2), p.253-259 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73085555 |
| source | Jstor Complete Legacy; MEDLINE |
| subjects | Aged Aged, 80 and over Antibodies Antibodies, Viral - blood Antigens Biological and medical sciences Chickenpox Vaccine Cohort Studies Dose-Response Relationship, Immunologic Drug Tolerance Female Herpes zoster Herpes Zoster - immunology Herpesvirus 3, Human - immunology Human viral diseases Humans Immunity Immunity, Cellular Immunization Immunization, Secondary Infectious diseases Interferon-gamma - biosynthesis Major Articles Male Medical sciences Middle Aged Older adults Random Allocation T lymphocytes T-Lymphocytes - immunology Vaccination Vaccines, Attenuated - adverse effects Vaccines, Attenuated - immunology Varicella zoster encephalitis Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye Viral Vaccines - adverse effects Viral Vaccines - immunology |
| title | Immune Response of Elderly Individuals to a Live Attenuated Varicella Vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T16%3A16%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20Response%20of%20Elderly%20Individuals%20to%20a%20Live%20Attenuated%20Varicella%20Vaccine&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Levin,%20Myron%20J.&rft.date=1992-08-01&rft.volume=166&rft.issue=2&rft.spage=253&rft.epage=259&rft.pages=253-259&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/166.2.253&rft_dat=%3Cjstor_proqu%3E30112921%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73085555&rft_id=info:pmid/1321859&rft_jstor_id=30112921&rfr_iscdi=true |